Macrogenics (MGNX) Total Current Liabilities (2012 - 2026)
Macrogenics (MGNX) posted quarterly Total Current Liabilities of $95.9 million for Q1 2026, up 73.05% year-over-year from $55.4 million in Q1 2025, and up 122.52% quarter-over-quarter from $43.1 million in Q4 2025.
Macrogenics (MGNX) Total Current Liabilities (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Total Current Liabilities for 15 consecutive years, with $95.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 73.05% year-over-year to $95.9 million; the TTM figure through Mar 2026 stood at $95.9 million (up 73.05% YoY), while the FY2025 annual figure was $43.1 million, down 22.36% from the prior year.
- Total Current Liabilities grew to $95.9 million in Q1 2026 per MGNX's latest filing, from $43.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $95.9 million in Q1 2026 and bottomed at $39.0 million in Q2 2025.
- Historically, Total Current Liabilities has averaged $54.2 million across 5 years, with a median of $51.3 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 34.82% — and 2026, when it surged 73.05%.
- Macrogenics' Total Current Liabilities stood at $48.6 million in 2022, then climbed by 15.42% to $56.1 million in 2023, then dropped by 1.03% to $55.5 million in 2024, then decreased by 22.36% to $43.1 million in 2025, then soared by 122.52% to $95.9 million in 2026.
- Business Quant data shows MGNX's Total Current Liabilities at $95.9 million in Q1 2026, $43.1 million in Q4 2025, and $44.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 95.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95.94 Mn |
| Dec 31, 2025 | 43.12 Mn |
| Sep 30, 2025 | 44.47 Mn |
| Jun 30, 2025 | 39.00 Mn |
| Mar 31, 2025 | 55.44 Mn |
| Dec 31, 2024 | 55.53 Mn |
| Sep 30, 2024 | 59.31 Mn |
| Jun 30, 2024 | 57.91 Mn |
| Mar 31, 2024 | 55.76 Mn |
| Dec 31, 2023 | 56.11 Mn |
| Sep 30, 2023 | 51.29 Mn |
| Jun 30, 2023 | 45.16 Mn |
| Mar 31, 2023 | 45.61 Mn |
| Dec 31, 2022 | 48.61 Mn |
| Sep 30, 2022 | 50.05 Mn |
| Jun 30, 2022 | 50.88 Mn |
| Mar 31, 2022 | 67.10 Mn |
| Dec 31, 2021 | 74.58 Mn |
| Sep 30, 2021 | 68.86 Mn |
| Jun 30, 2021 | 69.92 Mn |